The lack of significant change among this subgroup of patients initially showing a less than 50% reduction in MMD during treatment with CGRP (pathway) mAbs could be either attributed to a chronic resistance to treatment or the presence of another headache subtype that responds less favorably to CGRP (pathway) mAbs treatment. Here, CALCA is linked to Headache.